Pharvaris N.V. (NASDAQ:PHVS) Sees Significant Growth in Short Interest

Pharvaris N.V. (NASDAQ:PHVS) saw a large increase in short interest in August. As of August 14th, there was short interest totaling 1,775,021 shares, an increase of 48.7% from the July 30th total of 1,193,401 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average daily volume of 638,201 shares, the short-interest ratio is currently 2.8 days.

Insider Activity

In other news, insider Anne Lesage sold 30,703 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47. Following the completion of the transaction, the insider owned 93,969 shares of the company’s stock, valued at $3,334,959.81. The trade was a 24.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Berndt Modig sold 2,292 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the transaction, the chief executive officer directly owned 130,625 shares in the company, valued at $4,541,831.25. The trade was a 1.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 121,325 shares of company stock valued at $4,270,425 over the last quarter.

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently made changes to their positions in PHVS. Quantbot Technologies LP acquired a new position in Pharvaris in the second quarter valued at $41,000. JPMorgan Chase & Co. increased its stake in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Barclays PLC purchased a new position in shares of Pharvaris in the 4th quarter worth about $77,000. CoreCap Advisors LLC purchased a new position in shares of Pharvaris in the 2nd quarter worth about $93,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Pharvaris in the 4th quarter valued at about $110,000.

Analyst Ratings Changes

Several analysts have commented on PHVS shares. HSBC raised shares of Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. New Street Research set a $60.00 price target on Pharvaris in a research note on Friday, August 14th. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a research report on Friday, August 14th. Finally, Morgan Stanley upped their target price on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.08.

Pharvaris Stock Performance

Pharvaris stock traded down $0.13 during trading on Tuesday, reaching $34.48. The company had a trading volume of 209,450 shares, compared to its average volume of 338,093. Pharvaris has a 12-month low of $20.65 and a 12-month high of $38.13. The stock’s 50 day moving average price is $34.64 and its two-hundred day moving average price is $30.82. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -11.33 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, research analysts expect that Pharvaris will post -3.15 earnings per share for the current year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.